1. Successful Rituximab Treatment in Thrombotic Thrombocytopenic Purpura Patients Complicated by Other Autoimmune Disorders: Two Case Reports
- Author
-
Satoko Osanai, Akihito Shinohara, Maya Kobayashi, Michiko Ryuzaki, Midori Ishiyama, Junji Tanaka, Norina Tanaka, Shoko Oshima, Kentaro Yoshinaga, Yuki Izuka, Masayuki Shiseki, Megumi Oishi, Hiroshi Kazama, Shotaro Hagiwara, and Aya Watanabe
- Subjects
medicine.medical_specialty ,Early introduction ,Thrombotic thrombocytopenic purpura ,Corticosteroid treatment ,Case Report ,Autoimmune hepatitis ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,rituximab ,0302 clinical medicine ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,Internal Medicine ,medicine ,Humans ,thrombotic thrombocytopenic purpura ,Objective response ,Purpura, Thrombocytopenic, Idiopathic ,Plasma Exchange ,Purpura, Thrombotic Thrombocytopenic ,autoimmune hepatitis ,business.industry ,General Medicine ,medicine.disease ,ADAMTS13 ,Immune thrombocytopenia ,immune thrombocytopenia ,030211 gastroenterology & hepatology ,Rituximab ,business ,medicine.drug - Abstract
We herein report two cases of thrombotic thrombocytopenic purpura (TTP) complicated by other autoimmune disorders, autoimmune hepatitis and immune thrombocytopenia, respectively. In both cases, corticosteroids were continuously administered for the treatment of preceding autoimmune disorders. However, a sufficient objective response for TTP was not obtained by plasma exchange and corticosteroid treatment. Once a week rituximab (375 mg/m2) treatment for 4 times was initiated within 2 weeks from the diagnosis. Both patients achieved a sufficient response, and have never had any recurrence as of the last follow-up dates. The early introduction of rituximab could be an effective treatment option in TTP patients complicated with other autoimmune disorders.
- Published
- 2021
- Full Text
- View/download PDF